![]() ![]() ![]() Macular. Protect Complete AREDS2: AREDS2 Multivitamin, Beta- Carotene Free. AREDS 2: Primary Results & Beyond. For those who have read about the primary findings in the abstract of the AREDS2 paper, the trial’s instructive secondary and sub- group findings may have gone unnoticed. Those findings are highlighted here, and help explain the current recommendation of the National Eye Institute. Patients with at least moderate AMD should consider taking – or continue to take – the original AREDS formula, with beta- carotene replaced by 1. The Linus Pauling Institute's Micronutrient Information Center is a source for scientifically accurate information regarding the roles of vitamins, minerals. Find patient medical information for FOLIC ACID on WebMD including its uses, effectiveness, side effects and safety, interactions, user ratings and products that have it. Tthe end of every century it is customary to reflect on the events of the past hundred years and to look toward the future, and in this lecture I should like to do. While folic acid is often considered to be a supplemental form of folate, there is an important distinction between these two different compounds. Muscle Surf Weight gain, weight loss, muscle building, protein, creatine, and other products. MacularProtect Complete AREDS2 is a convenient, all-in-one formula providing powerful protection for macular & whole body health. It offers nutrients at levels found. The primary objective was to determine whether the addition of lutein/zeaxanthin (L+Z) or omega- 3 fatty acids (omega- 3s ) to the AREDS formula would be more effective in reducing the 5- year risk of advanced AMD or cataract (results of the cataract portion of the trial were published separately) . Another goal was to assess whether eliminating beta- carotene or changing zinc levels in the original AREDS formula would affect risk of progression. To accomplish these goals, all participants were randomly assigned to receive daily: L+Z (1. The placebo group served as controls. Patients also received either the original AREDS formula or a modified AREDS formula with no beta- carotene and/or lower zinc. Results A description of participants’ baseline characteristics can be found in Edu. Facts Vol. Fifty- nine percent (5. AMD in one eye and mean visual acuity of 2. About 5. 0% of AREDS2 participants were former smokers, and another 7% were current smokers. Those who smoked and those who had stopped less than a year prior to enrolment were excluded from receiving beta- carotene. Serum Levels of Lutein & Zeaxanthin: After 5 years, serum levels of lutein and zeaxanthin in those receiving L+Z and getting a beta carotene- containing AREDS formula were significantly lower than those getting L+Z and no beta- carotene. The three carotenoids compete with each other for absorption, and this finding indicates that high dose beta- carotene interferes with the absorption of lutein and zeaxanthin. Primary analyses: Compared to taking only the AREDS formula (controls), neither L+Z nor omega- 3s co- supplemented with an AREDS formula met the 2. Main Effects Analyses: Comparing participants who received L+Z to those who did not, showed a 9% reduction in risk of progression for the L+Z group. Secondary Randomization Analyses: Participants in the secondary randomization who were assigned to formulas with nobeta- carotene were compared to those receiving formulas that contained beta- carotene. Eliminating this carotenoid did not curb the protective effect of the AREDS formula against developing advanced AMD, as the removal of beta- carotene had no significant effect on risk of progression. Similarly, comparing formulas modified with low dose zinc (2. However a trend favoring better protection was observed for the higher dose of zinc. An 1. 8% lower risk of advanced AMD was seen for participants taking no beta- carotene plus L+Z. Essentially, this analysis addressed the question ? ![]() ![]() ![]() ![]() Safety Lung cancers were observed in 2% of participants who took AREDS containing beta- carotene compared to 0. Lutein/zeaxanthin was not associated with lung cancer risk. Thus, lutein and zeaxanthin appears to be a safer choice for former smokers. ![]() AFTER MY PREVIOUS BLOG ON MERCURY, I’m sure many of you are depressed and discouraged about mercury and its toxic effects. The bad news is today I am going to. No clinically or statistically significant differences in adverse events were seen when comparing the low versus high dose zinc groups. Comments. The preponderance of evidence from AREDS2 suggests that lutein and zeaxanthin offer some protection against AMD advancement. Though subgroup analyses are rigorously interpreted with a measure of caution, many of the secondary and sub group analyses were pre- specified to be evaluated in the study’s design. The apparent competitive absorption between high dose beta- carotene and lutein/zeaxanthin may have reduced the ability of the study to detect a significant impact of L+Z on progression to advanced AMD compared to controls. Importantly, L+Z appeared to benefit those with inadequate intake of these carotenoids. While AREDS2 patients were generally well nourished, their intake of lutein and zeaxanthin is not representative of the general US population, where low consumption is common. The authors suggest that a greater reduction in risk may have been seen if the subjects’ diets had more closely resembled that of the overall population. Though not discussed above, results from the age- related cataract portion of AREDS2 indicate that those consuming insufficient levels of lutein and zeaxanthin also gained some protection. While L+Z plus an AREDS formula did not help reduce the risk of progression to cataract surgery, there was a 3. A 3. 0% lower risk of developing any cataract – and a 3. Omega- 3 fatty acids demonstrated no benefit above and beyond that conferred by the AREDS formula to those with at least moderate AMD. Whether or not the omega- 3s have a role in the primary prevention of AMD awaits further investigation. The AREDS2 Research Group. Lutein + zeaxanthin and omega- 3 fatty acids for age- related macular degeneration. JAMA Ophthalmol Epub ahead of print, May 5, 2. The AREDS2 Research Group. Lutein/Zeaxanthin for the treatment of age- related cataract. AREDS2 randomized trial report No. JAMA Opthalmol Epubm ahead of print May 5, 2. An error occurred while setting your user cookie. Please set your. browser to accept cookies to continue. This cookie stores just a. ID; no other information is captured. Accepting the NEJM cookie is.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
November 2017
Categories |